Dopaminergics & Catecholamines

Navigation

Upward Index: 02 - Compounds & Molecules MOC | Literature Dossier: Dopaminergics & Catecholamines - References

---

1. Pharmacodynamics & Mechanism of Action

Catecholaminergic interventions target the enzymatic cascade that synthesizes Dopamine (DA), Norepinephrine (NE), and Epinephrine (Epi) across the mesocorticolimbic, nigrostriatal, and locus coeruleus networks: $\text{L-Phenylalanine}\underset{{\text{BH}}_4,{\text{Fe}}^{2+}}{\overset{\text{PAH}}{\to }}\text{L-Tyrosine}\underset{{\text{BH}}_4,{\text{Fe}}^{2+},{\text{O}}_2}{\overset{\text{Tyrosine Hydroxylase (TH)}}{\to }}\text{L-DOPA}\underset{\text{P5P (B6)}}{\overset{\text{AADC}}{\to }}\text{Dopamine}\underset{{\text{Vit C, Cu}}^{2+}}{\overset{\text{DBH}}{\to }}\text{Norepinephrine}$

• L-Tyrosine & Rate-Limiting TH Saturation: Tyrosine Hydroxylase (TH) is the rate-limiting enzyme of catecholamine synthesis and is normally $\sim 75\%$ saturated at baseline. However, under acute physiological or cognitive stress (sleep deprivation, cold exposure, prolonged executive load, or stimulant-induced vesicular depletion), neuronal firing rates increase and activate TH via phosphorylation at $\text{Ser}40$—making intracellular L-Tyrosine availability rate-limiting. Exogenous L-Tyrosine restores prefrontal working memory and cognitive flexibility without overstimulating basal catecholamines.
• Bromantane (Adamantylbromphenylamine / Ladasten): Synthetic actoprotector that acts via epigenetic histone deacetylase (HDAC) inhibition and PKA/CaMKII signaling at the TH and AADC (DDC) gene promoters. Within $60\text{–}120\text{ min}$, Bromantane increases hypothalamic and striatal Tyrosine Hydroxylase mRNA and protein expression by $+2\text{- to }2.5\text{-fold}$, increasing de novo dopamine synthesis capacity rather than forcing vesicular dumping (preventing post-stimulant crash and receptor downregulation).
• Mucuna Pruriens (L-DOPA) vs. TH Precursors: Standardized Mucuna pruriens supplies direct L-DOPA, bypassing the homeostatically regulated Tyrosine Hydroxylase step. While effective for acute prolactin suppression or transient reward enhancement, chronic daily L-DOPA downregulates endogenous TH activity and induces peripheral decarboxylation via AADC unless paired with a peripheral AADC inhibitor (such as EGCG from green tea extract).

---

2. Pharmacokinetics & Transporter Competition

• LAT1 Transporter Competition: L-Tyrosine crosses both the intestinal epithelium and the blood-brain barrier via the Large Neutral Amino Acid Transporter (LAT1 / SLC7A5), competing directly with L-Tryptophan and Branched-Chain Amino Acids (Leucine, Isoleucine, Valine). Consequently, L-Tyrosine must be ingested fasted ($\ge 45\text{ min}$ before or $2\text{ hours}$ after protein meals).
• L-Tyrosine vs. N-Acetyl-L-Tyrosine (NALT): While NALT is highly water-soluble, human clinical pharmacokinetic studies demonstrate that $35\text{–}56\%$ of administered NALT is excreted unchanged in the urine due to incomplete renal acylase deacetylation; free-form L-Tyrosine raises plasma tyrosine concentrations $2.5\text{–}3\times$ more effectively per milligram than NALT.
• Bromantane Absorption: Highly lipophilic adamantane structure ($T_{\max }\approx 2.75\text{–}4.0\text{ hours}$ orally, $t_{1/2}\approx 11.3\text{ hours}$). Sublingual administration dissolved in caprylic/MCT oil or intranasal delivery bypasses slow GI dissolution and first-pass hydroxylation.

---

3. Dosing, Cycling & Synergies

• Standard Protocol:
  • L-Tyrosine: $500\text{–}2,000\text{ mg}$ fasted upon waking or $60\text{ min}$ prior to high-stress cognitive/physical demand (military cold/sleep-deprivation studies use up to $100\text{–}150\text{ mg/kg}$).
  • Bromantane: $25\text{–}50\text{ mg}$ sublingually (in lipid carrier) or $50\text{–}100\text{ mg}$ orally in the morning. Cycle 4 weeks on / 2 weeks off.
  • Mucuna Pruriens ($15\text{–}98\%$ L-DOPA): Limit to $50\text{–}150\text{ mg}$ L-DOPA equivalent maximum 1–2x/week, paired with $200\text{–}400\text{ mg}$ EGCG (inhibits peripheral AADC).
• Obligate Enzymatic Cofactor Stack:
  • Vitamin B6 (as P5P): $10\text{–}25\text{ mg}$ (cofactor for AADC conversion of L-DOPA $\to$ Dopamine; see Methylation & B-Complex).
  • Vitamin C ($500\text{ mg}$) & Copper ($1\text{–}2\text{ mg}$): Cofactors for Dopamine $\beta$-Hydroxylase (DBH).
  • 5-MTHF & Vitamin C: Recycle oxidized dihydrobiopterin (${\text{BH}}_2$) back to Tetrahydrobiopterin (${\text{BH}}_4$), the essential cofactor for Tyrosine Hydroxylase.
• Contraindications & Biomarkers to Monitor:
  • Contraindications: Irreversible MAOIs (risk of hypertensive crisis), hyperthyroidism/Graves’ disease (tyrosine is the direct backbone of $T_3/T_4$ thyroid hormones), melanoma (tyrosinase converts tyrosine into melanin), and competitive WADA-tested sports (Bromantane is prohibited under class S6a).
  • Biomarkers: Serum Prolactin (inverse marker of tuberoinfundibular D2 dopaminergic tone), Free T3 / Free T4 / TSH, Resting Blood Pressure & HRV, and Homovanillic Acid (HVA) / Vanillylmandelic Acid (VMA) on organic acids testing.

---

4. Key Scientific Evidence Summary

• Systematic Review of L-Tyrosine: Jongkees et al. (2015) reviewed 35 human studies in Journal of Psychiatric Research, confirming that L-Tyrosine reliably reverses working memory and information processing deficits induced by acute stress, cold exposure, and sleep deprivation by replenishing depleted catecholamine stores.
• Bromantane TH Gene Expression: Vakhitova et al. (2004) and Morozov et al. (2000) demonstrated that Bromantane increases hypothalamic Tyrosine Hydroxylase and DOPA Decarboxylase gene expression by $>200\%$, improving work capacity and reducing asthenia in multicenter clinical trials ($N=728$).

See full study breakdowns in Dopaminergics & Catecholamines - References.